title: Comparison of radioimmunotherapy and external beam radiotherapy in colon cancer xenografts.
abstract: Radioimmunotherapy and external beam radiotherapy were compared in a nude mouse human colon cancer model. Radioimmunotherapy was delivered by intraperitoneal injection of 90Y-labeled anticarcinoembryonic antigen monoclonal antibody (anti-CEA MAB). Single fraction external beam radiotherapy was delivered using a 60Co teletherapy unit. Control groups received saline, unlabeled anti-CEA monoclonal antibody and labeled nonspecific monoclonal antibody. Subcutaneous CEA-expressing LS174T human colon carcinoma tumors were measured over time. Tumor growth suppression was expressed as delay to reach 2g compared to saline controls. Unlabeled anti-CEA monoclonal antibody and labeled nonspecific monoclonal antibody had no effect. External beam radiotherapy of 300, 600, 1000 and 2000 cGy produced growth delays of 3, 12, 17, and 22 days, respectively. Radioimmunotherapy with 120 microCi, 175 microCi, and 225 microCi resulted in growth delays of 20, 34, and 36 days. Estimated absorbed tumor dose was 1750 cGy in the 120 microCi group. Similar comparisons were done with the more radioresistant WiDr human colon carcinoma cell line. External beam radiotherapy doses of 400, 800, 1200, and 1600 cGy resulted in growth delays of 6, 21, 36 and 48 days, respectively. Radioimmunotherapy of 120 microCi and 175 microCi resulted in growth delays of 9 and 19 days, respectively. The 120 microCi dose delivered an estimated absorbed tumor dose of 1080 cGy to WiDr tumors. In summary, for the radiosensitive LS174T line, radioimmunotherapy produced biologic effects that were comparable to a similar dose of single fraction external beam radiotherapy. For the more radioresistant WiDr tumor, radioimmunotherapy produced a biologic effect which was less than a similar dose of single fraction external beam radiotherapy. These studies suggest that a tumor's response to radioimmunotherapy relative to that of external beam radiotherapy is, in part, dependent on tumor radiosensitivity and repair capacity.
authors.affiliation: General Oncologic Surgery, City of Hope National Medical Center, Duarte, CA 91010.
authors.forename: R R
authors.initials: RR
authors.lastname: Buras
authors.forename: J Y
authors.initials: JY
authors.lastname: Wong
authors.forename: J A
authors.initials: JA
authors.lastname: Kuhn
authors.forename: B G
authors.initials: BG
authors.lastname: Beatty
authors.forename: L E
authors.initials: LE
authors.lastname: Williams
authors.forename: P M
authors.initials: PM
authors.lastname: Wanek
authors.forename: J D
authors.initials: JD
authors.lastname: Beatty
mesh_terms: D000818:Animals; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000532:radiotherapy*; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D016499:Radioimmunotherapy; D014183:Transplantation, Heterologous; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
chemical_list: D003037:Cobalt Radioisotopes; D015021:Yttrium Radioisotopes